Lexaria Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Lexaria Corp. (Lexaria Bioscience Corp.) on December 14, 2015. The report discloses the entry into a material definitive agreement and unregistered sales of equity securities.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The specific financial transaction disclosed involves:
- Compensation: $2,500 cash and 50,000 common shares.
- Share Price: $0.20 per share.
- Total Value: $12,500 (calculated as $2,500 cash + $10,000 in shares).
Material Changes
On December 14, 2015, the Company entered into an Investor Relations contract with Radius Consulting Inc. for a 45-day term. This agreement resulted in the issuance of unregistered securities to one accredited investor under Rule 506 of Regulation D.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the securities were not registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the accreditation status of the investor receiving the 50,000 shares.
- Confirm the scope of services provided by Radius Consulting Inc. under the 45-day term.
- Review the press release (Exhibit 99.1) for additional context on the private placement.
- Check subsequent filings for the impact of this share issuance on total outstanding shares.